sort of. but if the company gets off pinks before they have

New Post Public Reply Private Reply Replies (0) Message Board
joey68 Dspetry #2924
382
sort of. but if the company gets off pinks before they have a structured company and are in the black, institutional investors will still wait several quarters to be sure any upward share price wasnt a fluke, which can make the share price drop.

all im saying is i take the uplist news as fluff. they shouldnt have talked about it right now; we still have investors trying to figure out if all three products theyre invested in is considered 'prosecco' yet the company wants to jump a tier?.. but hey, i could be wrong.

Iconic Brands, Inc. (ICNB) Stock Research Links

ICNB Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Testing Grounds: Navigating PRN Test Insights

Updated Category News Views 1

Deciphering the PRN Tester Repetition Today we're staring at what feels like déjà vu—a simple PR test peppered with the classic sentence about a fox and a dog. It's like someone left the 'repeat' function stuck on during a slow day at the office. But hey, let’s dig in. Is there something more behind this repetitive text, or are we grumbling at a wall? Unpacking the...

Continue Reading
TECNO's Modular Phone and Mini-PC Win Big at IFA 2026

Updated Category News Views 1

The Tale of Two Game-Changers TECNO has just scooped up two big-time awards, and I'm here to break it down like no glossy magazine ever could. Picture this: a brand that knows how to keep its foot on the innovation pedal and doesn't shy away from shaking up the tech world. TECNO's got the goods, claiming two prestigious IFA Global Product Technology Innovation Awards this...

Continue Reading
HKC and KOORUI Shine Bright at 2026 Berlin Awards

Updated Category News Views 3

Display Titans Take Center Stage in Berlin Look, in this game of display tech, you either adapt or get left in the dust. At the 2026 Global Product Technology Innovation Awards in Berlin, we saw two names rise to the top—HKC and its acclaimed brand KOORUI. They didn't just show up; they grabbed the spotlight with two major honors. Award Spotlights: A Breakdown HKC took...

Continue Reading
Signant and Lothar Forge Future in Clinical Trials

Updated Category News Views 2

Breathing New Life into Clinical Trials Alright, folks, listen up. We've got a fresh collaboration cooking that could shake things up in the clinical trial sector. Signant Health, a heavyweight in clinical trial solutions, has teamed up with Lothar Medical, and they’ve hitched their wagons to launch something rather intriguing: the ALDS PRO pulmonary function tech. Let...

Continue Reading
LiberNovo Spotlights Ergonomic Seating at Berlin's IFA 2026

Updated Category News Views 1

LiberNovo Sets the Stage at IFA 2026 If you're poking around Berlin this September, the Messe Berlin is the place to be, especially for those keeping tabs on the consumer tech world. LiberNovo, the ergonomic seating company you might not have had on your radar, is out here making noise. They're throwing down the gauntlet with the Maxis Series, promising a better deal for...

Continue Reading
Affleck Joins Aflac in Unlikely Yet Fitting Alliance

Updated Category News Views 2

A Partnership Born from a Punning Connection Look, in this world of insurance and Hollywood glitz, it's not every day you see Ben Affleck sharing the screen with a talking duck. But here we are. Aflac—the giant in supplemental health insurance—and Ben Affleck have cozied up for a series of ads under Affleck’s direction, breathing life into what started as nothing...

Continue Reading
Hims & Hers Faces Legal Storm Over Alleged Privacy Breaches

Updated Category News Views 4

Legal Storms Brew Over Alleged Privacy Breaches Well, here we go again, folks. Just when you think the waters are calming, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself in the thick of a nasty securities fraud class action lawsuit. Allegedly they've been less than honest with their customers' health info—something about sneaking around with people's sensitive data...

Continue Reading
Evolve & ELITEWHEELS: Shifting Gears in European Cycling

Updated Category News Views 3

Revving Up for the European Cycling Scene There's something about the open road and the whirr of wheels that gets blood pumping—maybe it's the competition, maybe it's the gear. Either way, this year's Italian Bike Festival is turning the Misano World Circuit into a battleground for cycling's elite, with evolve and ELITEWHEELS charging at the forefront. They're not just...

Continue Reading
Virterion Surges Ahead in VPS Racing With Reliable Hosting

Updated Category News Views 3

Why Virterion Stands Out in 2026 VPS Landscape For anyone knee-deep in the hosting game, you know the market's got more players than a late-night poker round. Virterion, though—that's a name carving out a noticeable niche, and for solid reasons. In 2026, the backdrop's not just speed, it’s about matching technology and support with what ambitious developers need. VPS...

Continue Reading
Roborock Fuels Market Surge with 27.6% Revenue Boost

Updated Category News Views 1

Roborock's Rocket-Like Ascent in Global Markets Call me impressed, but Roborock is really hitting its stride. The company's been on a tear, pulling in RMB 10.084 billion during the first half of 2026—a remarkable 27.6% bump from last year. Not just content with the revenue surge, they also saw net profits jump 45.6%, making it pretty clear that they're not just playing...

Continue Reading

Top 5 Most Recently Viewed Articles

Talisker Resources Successfully Closes Gold-Linked Note Deal

Updated Category News Views 49

Talisker Resources Announces Successful Financing Initiative Talisker Resources Ltd. (TSK) has made headlines with the completion of its latest financing venture involving $1.33 million through the issuance of gold-linked notes. This strategic move is set to propel the progress of Talisker's flagship project, the Bralorne Gold Project, which is currently undergoing...

Continue Reading
FDA Approves Novartis' Kisqali, Expanding Breast Cancer Treatment

Updated Category News Views 133

FDA Approves Novartis' Kisqali: A Major Step Forward in Breast Cancer Care Novartis (NYSE: NVS) has reached a crucial milestone with the FDA's approval of Kisqali (ribociclib), now available for a broader group of patients facing early-stage breast cancer. This approval represents a significant leap in treating hormone receptor-positive/human epidermal growth factor...

Continue Reading
Mounting Challenges for Mobileye N.V: Insights into Stock Outlook

Updated Category News Views 101

Mobileye Faces Downgrade as Transition Year Approaches Recently, UBS has revised its outlook on Mobileye N.V (NASDAQ:MBLY), a leader in autonomous driving technologies. The firm has downgraded the stock from Buy to Neutral, with a lowered price target of $14.00, decreasing from an earlier target of $20.00. This decision is primarily due to the company's current struggles,...

Continue Reading
Plans for Spending Cuts and Subsidy Eliminations Revealed

Updated Category News Views 118

Plans for Federal Spending Cuts and Subsidy Eliminations John Paulson, a billionaire investor known for his connections with former President Donald Trump, has outlined his strategy for significant federal spending reductions if he were to be appointed as Treasury Secretary. Collaborating with Elon Musk, Paulson seeks to minimize government expenditures, particularly by...

Continue Reading
Brazil’s Finance Minister Prepares for Key Fiscal Announcements

Updated Category News Views 35

Brazil's Finance Minister Prepares for Key Fiscal Announcements Brazil's Finance Minister Fernando Haddad has recently indicated that significant fiscal measures aimed at supporting the country’s financial framework might be unveiled shortly. This announcement comes as the government approaches the final stages of preparation for what could be a pivotal moment in...

Continue Reading